EU backs Swedish cancer treatment research with quasi equity investment
The European Investment Bank (EIB) has signed a €40 million (SEK 416m) loan agreement with Swedish biotech company Oncopeptides AB. The financing will support research, including phase 3 clinical studies of the lead candidate melflufen, and the expansion of the company. The EU bank's loan is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the main pillar of the Investment Plan for Europe under which the EIB and the European Commission are working together as strategic partners, with the EIB's financing operations boosting the competitiveness of the European economy.
- EIB signs €40 million loan agreement with Swedish biotech company Oncopeptides to support their long-term research and expansion.
- Financing will support R&D, product development and commercialisation of Oncopeptides' drug candidates for treatment of rare haematological cancers.
- The EIB loan is backed by the Investment Plan for Europe of the European Commission, which allows the EIB to support innovative projects.
Each year, approximately 3 in every 10,000 people are diagnosed with multiple myeloma, for which there is no cure. Therefore, a key focus of treatment is extending and improving the quality of life for patients. Oncopeptides' Melflufen is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload. A New Drug Application of Melfufen has been granted priority review by the U.S. Food and Drug Administration, FDA, for treatment of patients with multiple myeloma. A target date for the review is set to February 28, 2021. Oncopeptides is currently conducting one clinical phase 3 study and six clinical phase 2 studies.
European Commissioner for Innovation, Research, Culture, Education and Youth, Mariya Gabriel, yesterday said:
“Investment in research and innovation is crucial towards achieving our goal to beat cancer, contributing to the development of effective health and care tools for the prevention, early diagnosis and successful treatment of the disease. This is why we are setting up a mission to fight cancer as part of the future Horizon Europe programme. By joining efforts across Europe, we will ensure that more people will live without cancer in the future, while increasing quality of life for those affected.”
EIB Vice-President Thomas Östros, yesterday noted:
“This is the kind of project that the Investment Plan for Europe was set up to support. There is still a market gap when it comes to what is called “non-dilutive growth capital”, allowing innovative, fast growing EU-based SMEs to grow without giving up ownership of their ideas or company. This quasi-equity instrument allows us to support EU in-house knowledge and expertise to flourish, we're very happy to get behind yet another innovative Swedish company that has ground-breaking plans for the future.”
Anders Martin-Löf, CFO of Oncopeptides yesterday said:
“As the company is approaching a potential commercialization of its lead product melflufen, several new financing options become available. The EIB facility is a flexible solution that can be drawn upon with limited dilution for the shareholders, which is highly valuable to the company in this transition phase. We are grateful for the support from the EIB and look forward to working together through the continued expansion of Oncopeptides.”
Latest News from
European values: COVID-19 emergency measures pose a “risk of abuse of power”28/10/2020 16:10:00
The Civil Liberties Committee urges the Commission to evaluate “first wave” national measures to assess their impact on citizens’ rights and freedoms.
Statement by President von der Leyen at the joint press conference with Peter Piot, Special Advisor to the President, on additional measures for the EU's response to coronavirus28/10/2020 16:08:00
Statement given by President von der Leyen at the joint press conference with Peter Piot, Special Advisor to the President, on additional measures for the EU's response to coronavirus.
‘Not there yet’: Rule of law conditionality trilogues continue28/10/2020 15:25:00
The talks by the EP and Council will continue on Thursday when the co-legislators will meet for the fourth trilogue on mechanism to link the EU funds to the respect of rule of law.
MEPs warn of attempts by some EU countries to silence and subdue critical media28/10/2020 14:33:00
Media freedom within the EU has deteriorated recently, says the Civil Liberties Committee, concerned about journalists faced with violence, harassment and pressure.
Commission proposes fishing opportunities in the Atlantic and North Sea for 202128/10/2020 11:33:00
The Commission yesterday published its proposal setting out catch limits for fish stocks in the Atlantic and the North Sea. Based on this proposal, EU fisheries ministers will set the final catch limits at the Council on 15-16 December, to apply as of 1 January 2021.
ESMA Adds UK Venues to Opinions on Third-country Trading Venues28/10/2020 10:25:00
The European Securities and Markets Authority (ESMA), the EU’s securities markets regulator, has updated the list of third-country venues (TCTV) in the context of the opinions on post-trade transparency and position limits under MiFID II and MiFIR.
EUR 17 billion EU SURE social bond listed on LuxSE28/10/2020 09:25:00
Luxembourg 27 October 2020: In the presence of European Commissioner for Budget and Administration Johannes Hahn and Prime Minister of Luxembourg Xavier Bettel, the Luxembourg Stock Exchange (LuxSE) yesterday marked the listing of the first social bond issued under the EU SURE programme.
Commission disburses €17 billion under SURE to Italy, Spain and Poland27/10/2020 16:10:00
The European Commission has disbursed a total of €17 billion to Italy, Spain and Poland in the first instalment of financial support to Member States under the SURE instrument.
Boeing WTO case: the EU gets formal green light to impose duties on U.S. imports27/10/2020 15:25:00
The Dispute Settlement Body of World Trade Organization (WTO) yesterday formally authorised the EU to take countermeasures against the United States.
EU-African Union relations: joint communiqué of the AU Peace and Security Council and the EU Political and Security Committee27/10/2020 14:10:00
On 26 October 2020, the African Union (AU) Peace and Security Council (AU PSC) and the European Union (EU) Political and Security Committee (EU PSC) held their 12th Annual Joint Consultative Meeting, virtually, as part of their regular dialogue within the framework of Article 17 of the Protocol Relating to the Establishment of the Peace and Security Council of the African Union, and the AU – EU partnership. The meeting was co-chaired by H.E. Ambassador Osama Abdelkhalek, Permanent Representative of the Arab Republic of Egypt to the AU and Chairperson of the AUPSC for October 2020 and H.E. Ambassador Sofie From- Emmesberger, Permanent Chair of the EU PSC.